This page aggregates IRLA's FDA catalysts from pdufa.bio's own calendar and decision archive. Each item links its own page, which names its source or says plainly that it has none. Facts and dates only; verify against primary FDA / SEC / company filings.
Q1 2028. The next catalyst for IRulya Therapeutics Inc. is LAM-001 (inhaled rapamycin) Phase 2b Phase 2b data (readout). That date is known to the quarter only. One further catalyst is scheduled after it. Dates are taken from FDA notices, company filings or ClinicalTrials.gov, and we do not publish a specific day when the source only gives a month or a quarter.
We have no measured history for IRLA itself. Across the whole study of 1,667 FDA decisions, the median stock rose 17.5% at its best point in the 120 trading days before the decision, but was only 2.4% higher the day before it. Most of the move happened before the answer arrived and was largely given back.
FDA publications, company filings with the SEC, company press releases and ClinicalTrials.gov, with share prices measured from daily closing data. Each FDA decision links its own page, which names its source or says plainly that it has none. Where an outcome was inferred from the price reaction rather than read from a filing, it is marked Inferred wherever it is listed.